Genaissance Pharmaceuticals Enters Into HAP(TM) Technology License Agreement With Novo Nordisk
Genaissance Pharmaceuticals, Inc. announced that it has licensed its HAP(TM) Technology to Novo Nordisk A/S for use in a drug development program. Under the terms of the agreement, Novo Nordisk will pay Genaissance license and service fees, including fees for genotyping clinical samples. Genaissance will have certain rights to develop and commercialize specified diagnostic products and services.
"We are pleased that Novo Nordisk chose our HAP(TM) Technology to address their pharmacogenomic need," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "Novo Nordisk has been utilizing our Good Laboratory Practices DNA and genotyping services and this agreement expands the scope of our work with them, demonstrating how our various pharmacogenomic capabilities can benefit our customer base."
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.